Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efalizumab, a reversible T-cell modulator for psoriasis.

Neil H Shear1, Richard G Langley, Vincent Ho

  • 1Sunnybrook & Women's College Health Sciences Centre, University of Toronto Medical School and Ventana Clinical Research Corp., Toronto, ON. neil.shear@sw.ca

Journal of Cutaneous Medicine and Surgery
|April 25, 2006
PubMed
Summary

Efalizumab, a monoclonal antibody targeting LFA-1, effectively treats psoriasis by preventing T cells from entering the skin. This targeted therapy demonstrates profound and reversible benefits in psoriatic skin histopathology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Summary of Research: Dupilumab Safety for Treating Infants to Adults with Moderate-to-Severe Atopic Dermatitis.

Advances in therapy·2026
Same author

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Dermatology and therapy·2026
Same author

Impact of early treatment of psoriasis on disease recurrence-Results from the STEPIn study.

Journal of the American Academy of Dermatology·2026
Same author

Accelerometric Assessment of Gastric Contractility Using the Atmo Wireless Motility Capsule.

Neurogastroenterology and motility·2026
Same author

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Dermatology and therapy·2026
Same author

Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial.

Journal of the American Academy of Dermatology·2026

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is an inflammatory skin disease driven by complex immune pathways.
  • Existing treatments for psoriasis have limitations in specificity, safety, and efficacy.
  • A need exists for targeted therapies addressing the underlying mechanisms of psoriatic inflammation.

Purpose of the Study:

  • To review the inflammatory pathway in psoriasis.
  • To discuss the mechanisms of action of efalizumab in suppressing skin inflammation.
  • To highlight the therapeutic potential of efalizumab for psoriasis treatment.

Main Methods:

  • Review of the inflammatory cascade in psoriasis.
  • Analysis of efalizumab's interaction with lymphocyte function-associated antigen 1 (LFA-1).

Related Experiment Videos

  • Examination of efalizumab's effects on T-cell trafficking and LFA-1 expression.

    • Main Results:

    • Efalizumab restrains T cells, including pathogenic CD8 memory T cells, from entering psoriatic skin lesions.
    • Treatment with efalizumab leads to rapid clearance of cell surface and intracellular LFA-1 via lysosomal degradation.
    • Pharmacodynamic studies show sustained LFA-1 saturation, correlating with clinical improvements.

    Conclusions:

    • Efalizumab effectively suppresses skin inflammation in psoriasis through specific mechanisms targeting T-cell-mediated immunity.
    • The drug's action on LFA-1 demonstrates a profound and reversible impact on psoriatic skin pathology.
    • Efalizumab represents a targeted therapeutic approach for managing psoriasis.